AstraZeneca plc Company Profile (LON:AZN)

Analyst Ratings

Consensus Ratings for AstraZeneca plc (LON:AZN) (?)
Ratings Breakdown: 5 Sell Rating(s), 13 Hold Rating(s), 11 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: GBX 4,788.80

Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016JPMorgan Chase & Co.Reiterated RatingNeutralGBX 4,800View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Shore CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Goldman Sachs Group Inc.Reiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2016Jefferies GroupBoost Price TargetHoldGBX 4,600 -> GBX 4,800View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/13/2016Credit Suisse Group AGReiterated RatingUnderperformGBX 4,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Berenberg BankBoost Price TargetBuyGBX 4,950 -> GBX 5,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/11/2016Morgan StanleyReiterated RatingOverweightGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/3/2016BNP ParibasReiterated RatingOutperformGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2016Deutsche Bank AGReiterated RatingBuyGBX 5,600View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Independent Research GmbHSet Price TargetSellGBX 3,650View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2016Societe GeneraleReiterated RatingBuyGBX 6,900View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016HSBCReiterated RatingHoldGBX 4,240View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Oddo SecuritiesReiterated RatingBuyGBX 5,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Charles StanleyUpgradeStrong-BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Sanford C. BernsteinSet Price TargetNeutralGBX 4,352View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/25/2016Barclays PLCReiterated RatingEqual WeightGBX 5,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/14/2016Liberum CapitalReiterated RatingBuyGBX 5,300View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016NatixisReiterated RatingNeutralGBX 4,456View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016Nomura Holdings Inc.Lower Price TargetHoldGBX 4,880 -> GBX 4,350View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/10/2016Bryan, Garnier & CoReiterated RatingBuyGBX 5,520View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/12/2016Baader BankReiterated RatingHoldGBX 4,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016AlphaValueUpgradeBuyGBX 4,640View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/4/2016S&P Equity ResearchSet Price TargetNeutralGBX 4,500View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016HandelsbankenReiterated RatingAccumulateGBX 5,220.30View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2016Pareto SecuritiesReiterated RatingSellGBX 3,855.35View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/27/2016SwedbankReiterated RatingBuyGBX 5,115.47View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016Nordea Equity ResearchReiterated RatingHoldGBX 4,698.35View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/16/2015Kepler Capital MarketsReiterated RatingReduceGBX 3,700View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/14/2015DanskeUpgradeHoldGBX 4,400View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/9/2015Redburn PartnersUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/7/2014Cenkos Securities LtdReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for AstraZeneca plc (LON:AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016$0.86N/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AstraZeneca plc (LON:AZN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for AstraZeneca plc (LON:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/4/2016GBX 1313.16%2/18/20162/18/20163/21/2016Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015GBX 57.501.33%8/13/20158/13/20159/14/2015Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca plc (LON:AZN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/27/2015Courtois,Jean-PhilippeInsiderBuy900GBX 4,423£39,807Tweet This Trade  Share This Trade on StockTwits
8/28/2015Soriot,PascalInsiderBuy76,300GBX 3,960£3,021,480Tweet This Trade  Share This Trade on StockTwits
5/7/2015Marc DunoyerInsiderBuy10,000GBX 4,397£439,700Tweet This Trade  Share This Trade on StockTwits
4/30/2015Ann CairnsInsiderBuy1,100GBX 4,455£49,005Tweet This Trade  Share This Trade on StockTwits
4/29/2015Shriti VaderaInsiderBuy3,500GBX 4,563£159,705Tweet This Trade  Share This Trade on StockTwits
4/28/2015Graham ChipchaseInsiderBuy1,100GBX 4,606£50,666Tweet This Trade  Share This Trade on StockTwits
4/27/2015Bruce BurlingtonInsiderBuy600GBX 4,662£27,972Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AstraZeneca plc (LON:AZN)
DateHeadline
07/25/16 08:50 PMHC Stocks Assessment: Relypsa Inc (NASDAQ:RLYP) AstraZeneca plc (ADR) (NYSE:AZN) - share market updates (press release)
07/25/16 08:50 PMNotable News Recap: AstraZeneca plc (ADR)(NYSE:AZN), U.S. Bancorp(NYSE:USB) - NYSE Journal (press release)
07/25/16 08:50 PMAstrazeneca PLC (AZN) Shares are Up 2.94% – Trade Calls - Trade Calls
07/22/16 02:41 PMAnalysts Watch-list Stocks: Astrazeneca PLC (NYSE:AZN) , Novo Nordisk A/S (NYSE:NVO) - Street Updates
07/22/16 10:54 AMAstraZeneca (AZN) Upcoming Earnings: What matter for investors? - The Voice Registrar
07/21/16 03:30 AMGalenica to buy biotech firm Relypsa for $1.5 bln, ahead of split - [Reuters - UK Focus] - Galenica has agreed to buy Relypsa (Xetra: 0RY.DE - news) for $1.53 billion, paying a big premium for the Californian biotech company to strengthen its Vifor Pharma unit ahead of splitting up the Swiss healthcare group. Galenica, which owns Switzerland's largest pharmacy network and the Vifor specialty pharmaceuticals business, said on Thursday that Relypsa's board had recommended acceptance of its $32 per share cash offer. Galenica's Vifor unit already has rights to Relypsa's drug outside the United States and Japan, so the deal will mean the company now has worldwide control of the product.
07/19/16 08:05 PMAstraZeneca gets EU approval for Qtern
07/19/16 08:05 PMAstraZeneca's (AZN) Tagrisso Hits Phase III Primary Endpoint
07/19/16 02:44 PMBallard Power Systems (NASDAQ:BLDP) & AstraZeneca plc (NYSE:AZN) Stocks in Focus - Money News (press release)
07/19/16 02:44 PMStock Analysis review: AstraZeneca PLC (NYSE:AZN) - News Oracle
07/19/16 02:41 PMU.S. FDA panel backs Valeant psoriasis drug with risk management - [Reuters - UK Focus] - Valeant Pharmaceuticals International Inc's experimental drug to treat the skin disorder psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory ...
07/19/16 08:53 AMSuccessful lung cancer drug trial boosts AstraZeneca
07/19/16 08:53 AMAstraZeneca : Gets EU Approval for Qtern to Treat Type 2 Diabetes
07/19/16 01:10 AMWill GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners? -
07/11/16 02:40 PMLarge Cap Drug Manufacturers – Major: AstraZeneca PLC (NYSE:AZN) - Twin County News
07/11/16 02:40 PMTwo Stocks to Watch: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) , Astrazeneca PLC (NYSE:AZN) - Street Updates
07/11/16 08:02 AMMay Says U.K. Must Defend Its Drugmakers From Overseas Takeovers -
07/08/16 03:03 PMWhat's The Market Potential For Relypsa Now That AstraZeneca's ZS-9 Is Indefinitely On Hold? - In late May, shares of Relypsa Inc (NASDAQ: RLYP) soared when the FDA rejected AstraZeneca plc (ADR) (NYSE: AZN)’s hyperkalemia drug ZS-9. The market is betting that the rejection will be good news for Relypsa’s Veltassa, which also treats hyperkalemia. Slingshot Insights recently held an expert call related to the impact the FDA ruling will have on Relypsa. The expert was the chief of cardiology and co-director of the Heart Institute at Stony Brook University. The expert explained how there are two main groups of hyperkalemia diagnoses: acute ...Full story available on Benzinga.com
07/08/16 01:27 PMWhy AstraZeneca PLC Stock Rose in June - AstraZeneca's stock deserves some lift, for more important reasons than currency exchange tailwinds.
07/07/16 10:38 AMAnalysts watching two Stocks: Astrazeneca PLC (NYSE:AZN) , Relypsa, Inc. (NASDAQ:RLYP) - Street Updates
07/06/16 03:00 PM[$$] Moderna Therapeutics Strikes $315M Deal With Vertex for Cystic Fibrosis Drugs -
07/04/16 06:41 AM[$$] Poetic visions help companies reach more prosaic goals - [at Financial Times] - When I opened Facebook recently, a survey popped up. Did I agree the social media platform was "good for the world"? The survey raises another question: whether such lofty objectives are useful ...
07/04/16 02:20 AM3 Brexit ‘buys’: AstraZeneca plc, Compass Group plc and Severn Trent plc -
07/01/16 10:46 AMAstraZeneca PLC (LON:AZN) price target held steady to GBX5,000 as recorded today by Exane BNP Paribas
06/28/16 07:08 AMAstraZeneca's Zavicefta approved in EU
06/28/16 02:37 AMShould you buy giant yielders AstraZeneca, Petrofac Limited and Taylor Wimpey plc? -
06/27/16 11:35 PMPRESS DIGEST- New York Times business news - June 28 -
06/27/16 07:25 AMAstrazeneca PLC (NYSE:AZN) Broker Price Targets For The Coming Week - Fiscal Standard
06/27/16 03:45 AMAstraZeneca Plc breached its 50 day moving average in a Bullish Manner : AZN-GB : June 27, 2016 -
06/27/16 03:40 AMShould you buy Neil Woodford’s top 3 holdings Imperial Brands plc, AstraZeneca plc & GlaxoSmithKline plc? -
06/24/16 07:02 AM[$$] Few bright spots in UK traders' sea of red - [at Financial Times] - As a sea of red swept across City traders' screens on Friday, investors took refuge in the few stocks with sufficient exposure to overseas currencies or gold to be able to ride out the Brexit financial ...
06/17/16 10:36 AMAstraZeneca PLC (NYSE:AZN) To FDA: No More Crestor Generics Until 2023
06/17/16 10:36 AMAstraZeneca PLC (LON:AZN) price target maintained to GBX4,240 as issued in a report today by HSBC
06/15/16 12:17 PM[$$] Brexit conspicuous by its absence in UK groups' annual reports - [at Financial Times] - Whatever the outcome of next week's vote in the UK on its EU membership, the country's companies face their biggest political risk of the past 50 years or more. Yet they are very bad at reporting on it, ...
06/14/16 07:52 AMAnalyst's Checklist Stocks: Skyline Medical Inc. (NASDAQ:SKLN) , Astrazeneca PLC (NYSE:AZN) - Street Updates
06/14/16 05:35 AMWill Shire plc and AstraZeneca plc protect your portfolio from the upcoming storm? -
06/13/16 10:44 AMWorthy Stock Update: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/13/16 10:44 AMPrice Target Summary: CenturyLink, Inc. (NYSE:CTL), AstraZeneca PLC (NYSE:AZN) - Beacon Chronicle
06/09/16 02:45 PMPut Volume Skyrockets as AstraZeneca plc (AZN) Slides - Schaeffers Research (blog)
06/06/16 11:01 AMEarnings in Focus: Wynn Resorts Ltd. (NASDAQ:WYNN), AstraZeneca PLC (NYSE:AZN) - Beacon Chronicle
06/06/16 11:01 AMAnalyst Buzz: AstraZeneca PLC (NYSE:AZN) - News Oracle
06/06/16 08:07 AMAstraZeneca’s Key Focus: Oncology -
05/31/16 03:00 AMWill AstraZeneca plc, Shire plc and Smith & Nephew plc help you survive Brexit? -
05/30/16 06:30 AMRelypsa Up on CRL for AstraZeneca Hyperkalemia Drug -
05/29/16 07:23 AMOddo Securities Reiterates Buy Rating for AstraZeneca plc (AZN) - Let Me Know About This - Oddo Securities Reiterates Buy Rating for AstraZeneca plc (AZN)Let Me Know About ThisAstraZeneca plc logo AstraZeneca plc (LON:AZN)'s stock had its “buy” rating restated by equities research analysts at Oddo Securities in a note issued to investors on Tuesday. They presently have a GBX 5,400 ($78.14) price objective on the ...and more »
05/27/16 09:55 PMNotable Analysts Recommendation to Monitor: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN) - Street Updates - InvestCorrectlyNotable Analysts Recommendation to Monitor: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN)Street UpdatesOn 5/26/2016, shares of Astrazeneca PLC (NYSE:AZN) fell -0.10% in trading session and finally closed at $29.95. The company most recent volume stood at 5.48 million shares as compared to average volume of 4.13 million shares. Over the one year trading ...Trader's Healthcare Focused Stocks: Astrazeneca PLC (NYSE:AZN) , Mallinckrodt plc (NYSE:MNK)Is storiesAstrazeneca PLC (NYSE:AZN) Analyst ReviewRisers & FallersAstrazeneca Plc (NYSE:AZN) Sellers Increased By 12.71% Their ShortsWall Street Hints and NewsThe Post -Sonoran Weekly Review -InvestCorrectlyall 10 news articles »
05/27/16 09:53 AM[$$] Denys Henderson, industrialist who split up ICI, 1932-2016 - [at Financial Times] - Sir Denys Henderson, who has died aged 83, was the Imperial Chemical Industries chairman who transformed an old British empire institution into two modern companies. The 1993 demerger into a commodity ...
05/27/16 07:25 AMTrader's Healthcare Focused Stocks: Astrazeneca PLC (NYSE:AZN) , Mallinckrodt plc (NYSE:MNK) - Is stories - Trader's Healthcare Focused Stocks: Astrazeneca PLC (NYSE:AZN) , Mallinckrodt plc (NYSE:MNK)Is storiesAstrazeneca PLC (NYSE:AZN) decreased -0.10% to $29.95 while traded 5.48 million shares on 5/26/2016. The stock price negotiated for value between $29.67 to $30.08 in recent trading session. During the past 52 weeks, the stock's price witnessed a ...Notable Analysts Recommendation to Monitor: Astrazeneca PLC (NYSE:AZN) , Allergan plc. (NYSE:AGN)Street UpdatesAstrazeneca PLC (NYSE:AZN) Analyst ReviewRisers & FallersAstraZeneca (LON:AZN) Broker RoundupShare Trading Newsall 7 news articles »
05/27/16 07:06 AMAstraZeneca plc (4.71%), Centrica plc (5.87%) and United Utilities Group plc (3.97%) are dividend WINNERS! -
05/27/16 04:54 AMRelypsa Scores Big Win When Pharma Rival Flops at FDA -

Social

About AstraZeneca plc

AstraZeneca plc logoAstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for cardiovascular and metabolic diseases; oncology; respiratory, inflammation and autoimmunity, and infection, neuroscience and gastrointestinal. Its medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. It also offers potassium-binding compound sodium zirconium cyclosilicate (ZS-9), a treatment for hyperkalaemia, a condition associated with increased mortality in patients with chronic kidney disease (CKD), diabetes mellitus (DM) and chronic heart failure (CHF).

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $61.71
  • 50 Day Moving Average: $4248.36
  • 200 Day Moving Average: $4124.84
  • P/E Ratio: 20.23
  • P/E Growth: 3.03
  • Market Cap: $58.87B
  • Current Year EPS Consensus Estimate: $3.96 EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: